A real world multicenter study assessing the effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients previously treated with direct-acting antiviral agents
Latest Information Update: 28 Dec 2022
Price :
$35 *
At a glance
- Drugs Ribavirin (Primary) ; Sofosbuvir/velpatasvir/voxilaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 08 Nov 2022 Results presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases
- 23 Aug 2022 New trial record
- 26 Jun 2022 Results presented at The International Liver Congress 2022